Related Experiment Video

Updated: Jun 14, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

17.5K

Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression

Sandesh J Marathe1,2, Emily W Grey1, Margaret S Bohm3

  • 1Department of Medicine, Division of Hematology and Oncology, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN USA.

Npj Metabolic Health and Disease
|March 17, 2025
PubMed

Insights

Retatrutide (RETA) significantly reduces pancreatic and lung cancer growth in preclinical models, offering potential cancer risk reduction benefits alongside weight loss. These anti-tumor effects persist even after weight regain.

Area of Science:

  • Metabolic disease research
  • Oncology
  • Immunology

Background:

  • Obesity treatments are evolving, but their effects on obesity-associated cancers are not well understood.
  • Weight loss medications may influence cancer development and progression.

Purpose of the Study:

  • To investigate the impact of retatrutide (RETA)-induced weight loss on pancreatic and lung cancer models.
  • To explore the underlying mechanisms of RETA's anti-tumor effects, including immune system modulation.

Main Methods:

  • Pre-clinical models of pancreatic and lung cancer were treated with retatrutide (RETA) or semaglutide.
  • Tumor growth, onset, and volume were measured.
  • Systemic and tumor microenvironment immune responses were analyzed, including cytokine levels and cell populations.

Main Results:

  • RETA significantly reduced pancreatic cancer volume (14-fold) compared to semaglutide (4-fold).
  • RETA delayed tumor onset and attenuated progression in both pancreatic and lung cancer models.
  • RETA induced durable anti-tumor immunity through immune reprogramming, characterized by elevated IL-6 and altered immune cell profiles.

Conclusions:

  • Retatrutide (RETA) demonstrates significant anti-cancer effects in preclinical models, reducing tumor burden and delaying progression.
  • RETA's benefits extend beyond weight loss, potentially offering reduced cancer risk and improved outcomes for patients.
  • Immune system reprogramming is a key mechanism behind RETA's persistent anti-tumor activity.
Keywords:
CancerEndocrine system and metabolic diseasesObesity

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

12.9K

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493